Diabetes Education News

FDA approved Medtronic’s next-generation continuous glucose monitor for people with diabetes, according to an industry press release.

Algorithms for initiating insulin among noncritically ill adults varied widely across 20 U.S. academic hospitals, according to a brief report published in Diabetes Technology & Therapeutics.

Worse physical function may be the factor contributing to an increased fracture risk for women aged 75 to 80 years with type 2 diabetes, according to a study published in JAMA Network Open.

Older adults with diabetes who spend less time within their individualized HbA1c target range have a higher risk for developing Alzheimer’s disease and dementias, according to findings published in JAMA Network Open.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

Quality testing of three counterfeit semaglutide products found low purity and more measured semaglutide than what was on the label, according to a research letter published in JAMA Network Open.

The number of monthly prescription fills for semaglutide increased by 442% from 2021 to 2023, according to a research letter published in JAMA Health Forum.

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

NEW ORLEANS — In part three of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Kimber Simmons, MD, MS, about how providers should discuss treatments for people with early-stage type 1 diabetes.